Abivax Société Anonyme has raised $920 million to support the development of obefazimod, a novel oral therapy for ulcerative colitis and Crohn’s disease. The funding extends the company's cash runway into the fourth quarter of 2029 and strengthens its position for possible mergers or acquisitions. While the stock is currently fairly valued in the $90 range, future upside depends on receiving a favorable label for ulcerative colitis and positive Phase 2b data for Crohn’s disease expected in 2027. The company carries risks including clarity on regulatory labeling, competition, and reliance on a single drug asset. The analyst maintains a Hold rating due to the drug’s blockbuster potential balanced against these uncertainties.
Abivax's recent $920 million funding round for its ulcerative colitis and Crohn’s disease drug development provides a backdrop for health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Sep 24, 2026 00:03 WIB: Of 100 priced US health-sector stocks tradable on Pluang, 14 rose and 85 fell. Notable movers include ACADIA Pharmaceuticals Inc. (ACAD) at USD 25.00 with a -5.34% change and a typical hold time of 77 days, Ascendis Pharma A/S (ASND) at USD 225.05 down 5.27% with a 55-day hold, and Ginkgo Bioworks Holdings Inc (DNA) at USD 8.90 down 5.02%, with a typical hold time of 10 days and Pluang order activity showing 37% sell and 63% buy.
Enova reported strong Q3 results with 33% adjusted EPS growth and 26% revenue growth, supported by a focus on business loans and a lower net charge-off ratio. Despite the failed acquisition of Grasshopper Bank, management plans to accelerate share bu...
A Bitcoin transaction on October 17 placed a 100-byte plaintext message in block 971,914 using an OP_RETURN output, which allows data to be recorded but not spent. This message, paying a fee of 253 satoshis, included text about quartz clocks and the ...
U.S. spot Bitcoin ETFs experienced a sharp reversal with $524.8 million in inflows on October 21 followed by $635.6 million in outflows on October 22 and another $137.9 million withdrawn on October 23. Despite these withdrawals, the net inflow for th...
Ethereum prices fell to the $2,350-$2,380 range following large sell-offs by BitMEX co-founder Arthur Hayes, who liquidated Ethereum and DeFi assets ahead of the Federal Reserve's critical policy meeting. This move reflects institutional caution amid...
Stellar Lumens (XLM) was trading at $0.1679 on October 25, slightly below the forecasted target of $0.174 set for October 27. This represents a 1.66% increase expected by the forecast, but the current price is down 1.08% over the past 24 hours. Techn...
